{
    "clinical_study": {
        "@rank": "88842", 
        "arm_group": {
            "arm_group_label": "Aortic Bioprosthesis, Model 11000", 
            "arm_group_type": "Experimental", 
            "description": "Aortic valve replacement therapy"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this observational trial is to gather further clinical data to confirm the\n      safety and performance of the Edwards Pericardial Aortic Bioprosthesis, Model 11000 in this\n      trial population."
        }, 
        "brief_title": "Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Aortic Valve Disorder", 
            "Aortic Valve Insufficiency", 
            "Aortic Valve Stenosis", 
            "Heart Failure", 
            "Coronary Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aortic Valve Insufficiency", 
                "Aortic Valve Stenosis", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Failure"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, non-randomized, non-controlled observational clinical trial. Up to\n      200 subjects will be enrolled at up to 6 participating clinical sites. The trial will\n      include male and female patients, 18 years or older, requiring replacement for a diseased,\n      damaged, or malfunctioning native or prosthetic valve. Patients will be followed and\n      assessed after implant for up to 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Require replacement of aortic valve\n\n          -  Signed informed consent\n\n          -  Willing to return to study site for follow-up visits\n\n        Exclusion Criteria:\n\n          -  Active endocarditis/myocarditis (< 3 months)\n\n          -  Myocardial infarction (< 30 days)\n\n          -  Renal insufficiency/ End-stage renal disease\n\n          -  Life expectancy (< 1 year)\n\n          -  Requires multiple valve replacement/repair\n\n          -  Requiring emergent aortic valve surgery\n\n          -  Pregnant or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651052", 
            "org_study_id": "2010-03"
        }, 
        "intervention": {
            "arm_group_label": "Aortic Bioprosthesis, Model 11000", 
            "description": "Implant of an aortic valve, Model 11000", 
            "intervention_name": "Heart Valve Surgery", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Aortic valve replacement/regurgitation", 
        "lastchanged_date": "October 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Krak\u00f3w", 
                        "country": "Poland", 
                        "zip": "31-202"
                    }, 
                    "name": "Krakowski Szpital Specjalistyczny im. Jana Paw\u0142a II"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland", 
                        "zip": "04-628"
                    }, 
                    "name": "Instytut Kardiologii im. Prymasa Tysi\u0105clecia Stefana Kardyna\u0142a Wyszy\u0144skiego"
                }
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000", 
        "overall_official": {
            "affiliation": "Edwards Lifesciences", 
            "last_name": "Carol Renner", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Descriptive information of early rates and late linearized rates of the follow-ing:\nStructural valve deterioration\nThromboembolism\nAll bleeding/hemorrhage\nMajor bleeding/hemorrhage\nAll paravalvular leak\nMajor paravalvular leak\nNon-structural valve dysfunction\nEndocarditis\nHemolysis\nAll cause mortality\nTrial valve-related mortality\nExplant", 
            "measure": "Safety Endpoints", 
            "safety_issue": "Yes", 
            "time_frame": "Intraoperative, discharge, 3 months, and annual scheduled follow-up visits (5 Years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651052"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Clinically acceptable hemodynamic performance confirmed by core lab evaluation of echocardiography\nNew York Heart Association (NYHA) functional class com-pared to baseline\nChange in Quality of Life questionnaires EQ-5D (EuroQol) and Short Form 12 version 2 (SF-12v2) from baseline/screening to 1-year", 
            "measure": "Performance Endpoints", 
            "safety_issue": "No", 
            "time_frame": "5-Years (at each scheduled follow-up visit)"
        }, 
        "source": "Edwards Lifesciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Edwards Lifesciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}